Login

Financial Snapshot

Revenue
TTM
$2.261B
Gross Margin
TTM
60.18%
Net Income
TTM
-$672.6M
Current Assets
2026 Q2
Current Liabilities
2026 Q2
Current Ratio
2026 Q2
203.67%
Total Assets
2026 Q2
Total Liabilities
2026 Q2
Book Value
2026 Q2
$1.479B
Cash
2026 Q2
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$41.23M

Stock Price

Loading...
Market Cap: $1.2629 Billion

About Enovis Corp

Enovis Corp (NYSE: ENOV) is a medical technology company. The filing excerpts provided do not contain sufficient detail to construct a fully source-grounded canonical description covering revenue model, segment breakdown, competitive position, headquarters, founding year, or leadership. All available excerpt content relates only to SEC cover-page boilerplate from the 10-K filed 2026-02-26 (accession 000142080026000012) for fiscal year ended December 31, 2025, and does not include the substantive business description sections required to meet the writing standards. A description cannot be responsibly completed from these excerpts alone.

Source: SEC 10-K, filed 2026-02-26

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: Abbott Laboratories Axonics, Inc. Conmed Corp Glaukos Corp Integer Holdings Corp Inari Medical, Inc. Integra Lifesciences Holdings Corp iRhythm Holdings, Inc NUVASIVE INC Tandem Diabetes Care Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support